DeutschNewstral
Article
jdsupra.com on 2023-12-11 21:30
Stelara® Biosimilar Updates: IPR Petition Challenging U.S. Patent No. 10,961,307 Filed and SB17 Settlement and Launch Date Announced
Related news
- Samsung Bioepis Files IPR Petition Challenging Regeneron Aflibercept Patentjdsupra.com
- Stelara® Biosimilar Updates: Settlement of IPR and FDA Review of Proposed Biosimilarjdsupra.com
- EYLEA® IPR Appeals Filedjdsupra.com
- The First Biosimilar Disputes at the Unified Patent Court (UPC)jdsupra.com
- PTAB Institutes Later-Filed IPR and Consolidates with Earlier-Filed IPR Challenging Different Claims of Same Patentjdsupra.com
- Biosimilar Makers’ IPR Strategy Yields Mixed Resultsjdsupra.com
- Judge Finds Biosimilar Patent Procedures Optionaljdsupra.com
- Alvotech and Teva’s Selarsdi™ (ustekinumab-aekn), Biosimilar to Stelara® Approved by FDAjdsupra.com
- Endo Pharma Patent Survives IPR Trialjdsupra.com
- Alvotech and Teva Announce Acceptance of BLA for AVT04, a Proposed Biosimilar to STELARA (ustekinumab)jdsupra.com
- Alvotech Announces More Settlements and Expected Launch Dates Regarding Biosimilar to STELARA (ustekinumab), AVT04jdsupra.com
- Supreme Court Will Judge Biosimilar Patent Dancejdsupra.com
- No Rehearing Of Biosimilar Patent Dance Decisionjdsupra.com
- How Will The Supreme Court Choreograph The Biosimilar Patent Dance?jdsupra.com
- Will You, Won't You Join The Biosimilar Patent Dance?jdsupra.com
- Remicade Biosimilar Closer To Approval, But Patent Dance Goes Onjdsupra.com
- Patent Infringement Suit Against Indemnitee Forecloses IPR Petition by Indemnitorjdsupra.com
- Biosimilar IPR Appeal Updatesjdsupra.com
- Federal Circuit Finds Biosimilar Patent Dispute Resolution Procedures Optionaljdsupra.com
- Amgen and Apotex do the Biosimilar Patent Dancejdsupra.com